Skip to content

Gemtuzumab ozogamicin

Mylotarg (gemtuzumab ozogamicin) is an antibody pharmaceutical. Gemtuzumab ozogamicin was first approved as Mylotarg on 2017-09-01. It is used to treat myeloid leukemia acute and myelomonocytic leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against myeloid cell surface antigen CD33.
Trade Name Mylotarg
Common Name Gemtuzumab ozogamicin
Indication myeloid leukemia acute, myelomonocytic leukemia acute
Drug Class Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)
Gemtuzumab ozogamicin
Get full access now